Recent News

Posted by Burton on May 25th, 2011 in Headlines  ⟩  0 comments

St. Louis, MO Lee Biosolutions has announced the introduction of a new Monoclonal Antibody anti-Human Apolipoprotein Apo A1 for cardiovascular research.

APOA-1 is a major protein of plasma High Density Lipoprotein. ApoA1 participates in the reverse transport of cholesterol from tissues to the liver for excretion. APOA1 is a cofactor for LCAT, which is responsible for the formation of most plasma cholesteryl esters.

Lee's monoclonal antibody was purified from Balb/C mice and immunized with highly purified human apoloipoprotein A-1. The mouse spleen and lymph node lymphocytes were fused to firm hybridomas. Lee Biosolutions purified Mouse IgG1 kappa antibody was purified from tissue culture fluid using protein a chromatography. the monoclonal antibody reacts with human apolipoprotein A-1 by elisa and blotting applications.

According to Burton Lee, "Lee Biosolutions is in constant communication with its customers to determine trends and anticipate product needs before they happen. Innovative purification procedures continues to be key to the success of Lee Biosolutions business. We are offering a number of related lipoproteins from ApoA1 to ApoE lipoporteins for research.

"We understand the critical role our products play in the clinical research process", Lee said. By maintaining higher purity and quality standards, we aim to provide clients with a wider variety of reliably consistent products which makes us the preferred producer of kidney proteinS.

Lee Biosolutions Inc is a leader in the development and marketing of high valued specialty products including Lipoproteins used in Cardiovascular and Lupas research.

Working closely with major diagnostic companies and clinical researchers worldwide in autoimmune studies, cardiovascular and cancer research, Lee Biosolutions, Inc delivers over 400 products to more than 40 countries around the globe. To learn more about how LEE BIOSOLUTIONS helps to make research work, visit www.leebio.com

Posted by Burton on May 25th, 2011 in Headlines  ⟩  0 comments

Lee Biosolutions increases production of Myeloperoxidase (MPO)
New research suggest that MPO can help breakdown toxic nanomaterials in humans

May 19, 2010; St. Louis, MO - In the minds of many, iPads and mini notebooks are among the "wonders" of the new age of computing. While this may be quite true, the technology that allows for computer chips to become smaller is made possible by the carbon nanotube - a material also proven to be harmful to workers handling it over long periods of time. The good news is that researchers at the University of Pittsburg have identified that the enzyme myeloperoxidase (MPO) can reduce the harmful effects of carbon nanotubes to exposed individuals. Lee Biosolutions, one of the forerunners in MPO production, is increasing its production of the enzyme to meet the demand these new findings will create.

According to Lee Biosolutions president, Burton Lee, carbon nanotubes are often referred to as a wonder material for many household items aside from electronics and compact computing devices, such as components in cars and anti-wrinkle chemicals in clothing. While not all nanotubes are proven dangerous, some behave much like asbestos in the lungs. The use of carbon nanotubes has significantly increased as electronics and plastics have become more prevalent, and the threat to exposed workers can lead to cancer 30 to 40 years down the road.

MPO is a peroxidase enzyme, most abundantly present in neutrophil granulocytes (a subtype of white blood cells). MPO has a heme pigment, which causes its green color in secretions rich in neutrophils, such as pus and some forms of mucus. In the human body, MPO produces hypochlorous acid (HOCl) from hydrogen peroxide (H2O2) and chloride anion (Cl-) during the neutrophil's respiratory burst, and requires heme as a cofactor. Hypochlorous acid is cytotoxic, so the MPO is used by the neutrophil to kill bacteria and other pathogens.

"Our native human myeloperoxidase (MPO) enzyme is already being used in cardiac and autoimmune assays in research worldwide. Demand for MPO will continue to increase as exposure to and handling of carbon nanotubes increases. We have an opportunity to counteract the many health issues we are just beginning to face, and Lee Biosolutions is prepared with continuous, increased production of MPO." said Lee.

For over 30 years, Lee Biosolutions has been providing proteins, enzymes and other materials to research facilities around the country that work to advance the healthcare industry. By providing Solutions on Demand, Lee Biosolutions has become the preferred source for materials such as myeloperoxidase (MPO). For more information, visit Lee Biosolutions at www.leebio.com.